Aptocine talaporfin sodium: Phase I started

Light Sciences began a single-arm, open-label, U.S. Phase I trial to evaluate 2 dosages of IV Aptocine using 50, 100, 150 or 200 J/cm of light in 18-24 patients ages 18-34 with PN tumors that are not ...